1. Introduction

Crohn’s disease (CD) is a chronic relapsing inflammatory bowel disease (IBD), affecting multiple sites of the gastrointestinal tract. More than 60% of CD patients have small bowel (SB) lesions. In order to improve the long-term outcomes, the concept of treat to target (T2T) has been adopted. Time-dependent objective treatment targets have been set out in the updated Selecting Therapeutic Targets in IBD recommendations, with the goal of treatment being mucosal healing and holistic remission. Endoscopy plays a crucial role in defining the site and extent of a disease in order to plan an optimal therapy. Small bowel capsule endoscopy (SBCE) is widely utilized because of its noninvasive and patient-friendly nature. It can visualize entire small-intestinal mucosa and facilitate detection of small intestinal abnormalities. However, SBCE is accompanied with a number of limitations and complications. Thus, there is an urgent need for developing sensitive and inexpensive biomarkers to employ SBCE for identifying IBD with the highest diagnostic efficacy.

Fecal calprotectin (FC) is a 36-kDa calcium and zinc-bind protein, secreted extracellularly by stimulated neutrophils or released by cell disruption or death. It has been proposed as a noninvasive surrogate marker of intestinal inflammation in inflammatory bowel disease. This study aimed to assess the capability of FC in predicting small bowel capsule endoscopy (SBCE) findings in pediatric patients with known Crohn’s disease (CD). We retrieved data of consecutive patients aged 2 to 17 years old who underwent SBCE from January 2017 to April 2020 and had endoscopic remission on ileocolonoscopy. Sixty-eight patients were included in the analysis. There were 13 patients with a weighted pediatric CD activity index ≥ 12.5, 47 patients with FC ≥ 200 μg/g, and 45 patients with significant small bowel (SB) inflammation [Lewis score (LS) ≥ 135]. The LS correlated weakly with FC (R = 0.30, P < .05). The area under the curve of FC as a surrogate diagnostic test for LS ≥ 135 was 0.691, and the optimal FC cutoff values were 242 μg/g with the corresponding sensitivity and specificity of 78% and 65%, respectively. The area under the curve of FC for moderate-to-severe inflammatory activity in the SB was 0.718. In patients with FC level ≥ 670 μg/g, LS ≥ 790 was found in 33% (9/27) of patients, with the sensitivity and specificity of 69% and 67%, respectively. FC may be used to predict SB mucosal inflammation in pediatric patients with confirmed CD having endoscopic remission on ileocolonoscopy.

2. Methods

2.1. Study design

This is a retrospective single-center observational study, approved by the Ethics Committee in Children’s Hospital of Fudan University. The inclusion criteria were as follows: CD patients aged 2 to 17 years old who underwent SBCE from January 2017 to April 2020, had a FC measurement within 1 week before SBCE, and the observation of endoscopic remission of FC in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease. Medicine 2022;101:42(e31163).

How to cite this article: Wang S, Miao S, Qiu X, Wu J, Wang Y. Fecal calprotectin in predicting small bowel capsule endoscopy findings in pediatric patients with known Crohn’s disease. Medicine 2022;101:42(e31163).

Accepted: 14 September 2022 / Received: 31 March 2022 / Received in final form: 11 September 2022 / http://dx.doi.org/10.1097/MD.0000000000031163

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

The authors have no funding and conflicts of interest to disclose. Informed consent was obtained from the patient for the purpose of publication. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

* Correspondence: Yuhuan Wang, Department of gastroenterology in Children’s hospital of Fudan University, Wanyuan Road 399, Minhang District, Shanghai (e-mail: wangyuhuan08@163.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
second European evidence-based Consensus on the diagnosis and management of CD.[8] Endoscopic remission was defined by a Simple Endoscopic Score for CD of < 4.[9]

2.2. SBCE
Eligible patients underwent SBCE with OMOM capsule (Jinshan Science & Technology Group, Chongqing, China). All videos were analyzed by experienced gastroenterologists who were blinded to FC results. The diagnosis of CD was carried out based on the mucosal findings on SBCE as described previously.[11] Lewis score (LS) was employed to measure the activity of SB inflammation in accordance with descriptions provided previously.[12] A LS < 135 indicated normal or insignificant mucosal inflammation, LS in the range of 135 to 790 represented mild mucosal inflammation, and LS ≥ 790 signified moderate-to-severe inflammation.[13]

2.3. FC testing
Stool samples of patients who were suspected of having pediatric CD were collected and kept in a specific FC collection container before undergoing SBCE. Samples were stored at 4°C and processed in batches by an external laboratory (Suzhou Herui Biotech Co, Ltd, Suzhou, China). FC levels were detected using enzyme-linked immunosorbent assay (BUHLMANN Laboratories AG, Schönenbuch, Switzerland). Measurement range was 30 to 1800 µg/g. According to the laboratory guidelines, FC levels > 200 µg/g indicated active CD.

2.4. Clinical data
Demographic and phenotypic data were collected, including weighted pediatric CD activity index (wPCDAI) and routine laboratory parameters. The wPCDAI is an overall score that classifies patients into 4 disease activity categories: none, <12.5; mild, 12.5 to 40; moderate, >40 to 57.5; and severe, >57.5.[14] Routine laboratory parameters included: C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), and albumin level within 2 weeks of SBCE. In addition, an elevated CRP level was defined as > 8 mg/L; elevated ESR was defined as > 21 mm/hour in males and > 26 mm/hour in females; a serum albumin level less than 39 g/L was defined as abnormal.

2.5. Statistical analysis
The levels of FC, LS, and wPCDAI were statistically analyzed. The correlation between LS and FC was assessed by the Pearson’s correlation analysis. The strength of correlation was defined according to correlation coefficient as follows: 0 to 0.19, very weak; 0.2 to 0.39, weak; 0.4 to 0.59, moderate; 0.6 to 0.79, strong; 0.8 to 1.0, very strong, with positive coefficients indicating positive correlation and negative coefficients indicating negative correlation.[15] P < .05 was considered statistically significant.

The sensitivity and specificity of FC in predicting SBCE findings was calculated at different cutoff values, as analyzed by receiver operating characteristic curve. Test characteristics were determined by using a 2 × 2 contingency table. Pearson’s chi-square test was used to analyze categorical variables. The data were statistically analyzed by using IBM SPSS statistic (version 20.0; Armonk, NY).

3. Results
3.1. Patients’ baseline characteristics
A total of 68 patients were enrolled in this study, including 42 males and 26 females with a median age of 11.73 years (range, 4–16 years). Among the 68 patients, there were 13 patients with wPCDAI ≥ 12.5. Although all of the 68 patients had endoscopic remission (Simple Endoscopic Score for CD < 4), 50 (74%) patients still had inflammatory lesions on SBCE (Fig. 1), and 45 (66%) had significant inflammatory activity (LS ≥ 135) on SBCE (Table 1). Of the 45 patients with significant inflammatory activity, there were 10 patients with wPCDAI ≥ 12.5.

3.2. FC testing and SBCE findings
Among the 68 patients, there were 64, 52 and 47 patients with FC ≥ 50 µg/g, FC ≥ 100 µg/g, and FC ≥ 200 µg/g, respectively. The mean FC value was 723.5 µg/g (± 700.7). The proportions of patients with LS ≥ 135 in FC ≥ 50 µg/g and FC < 50 µg/g groups (67% vs 50%, P = .481), and in FC ≥ 100 µg/g and < 100 µg/g groups (71% vs 50%, P = .118) were similar. In the FC ≥ 200 µg/g group, there were significantly more patients with LS ≥ 135 than in FC < 200 µg/g group (74% vs 48%, P = .031); however, the mean of LS and wPCDAI had no significant difference between these 2 groups (Table 2).

Figure 1. SB ulcers as seen on capsule endoscopy in pediatric CD patients. CD = Crohn’s disease, SB = Small bowel.

### Table 1
Patients’ demographic and clinical characteristics.

| Character | Value |
|-----------|-------|
| Gender, male/female | 42/26 |
| Age, years, median (range) | 11.73 (4-16) |
| wPCDAI | |
| < 12.5 | 56 |
| ≥ 12.5 | 12 |
| Positive SBCE findings | 50 |
| Minor lesions without LS | 5 |
| LS 135-790 | 32 |
| LS > 790 | 13 |
| FC (µg/g) | |
| <200 | 21 |
| ≥200 | 47 |
| CRP elevated | 5 |
| ESR elevated | 19 |
| ALB abnormal | 1 |

ALB = albumin, CD = Crohn’s disease, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, FC = fecal calprotectin, LS = Lewis score, SBCE = small bowel capsule endoscopy, wPCDAI = weighted pediatric Crohn’s Disease activity index.
The mean LS was 486.4 (±729.7, range: 0–3933). There was a weak correlation between final LS and FC values ($r_s = 0.30; P = .015$), and no correlation between LS and ESR, albumin or wPCDAI. FC values showed statistically significant but weak correlation with ESR ($r_s = 0.31; P = .011$) and albumin ($r_s = −0.31; P = .011$).

### 3.3. Predicting mild inflammatory activity in small bowel

The area under the cure (AUC) of FC as a surrogate diagnostic test for LS $≥ 135$ on SBCE was 0.691 (95% confidence interval, 0.555–0.828, $P = .010$) (Fig. 2). The optimal FC cutoff values were 242 µg/g with a corresponding sensitivity and specificity of 78% and 65%, respectively. The sensitivity and specificity for significant inflammatory activity (LS $≥ 135$), according to the FC cutoff values, is shown in Table 3.

### 3.4. Predicting moderate-to-severe inflammatory activity in small bowel

The AUC of FC for moderate-to-severe inflammatory activity in the SB was 0.718 (95% confidence interval, 0.581–0.856, $P = .015$) (Fig. 3). The optimal FC cutoff values were 670 µg/g with a corresponding sensitivity and specificity of 69% and 67%, respectively. The sensitivity and specificity for significant inflammatory activity (LS $≥ 790$), according to the FC cutoff values, is shown in Table 4.

### 4. Discussion

To the best of our knowledge, although there were studies showing that FC could be used as a screening tool before undergoing SBCE,[16] this is the first study that evaluated the role of FC in predicting SBCE findings in pediatric patients with known CD.

Endoscopic remission is an important treatment goal in CD that is associated with improved clinical outcomes, including reduced hospitalization and surgery rates.[13] Change in the treatment should be considered if endoscopic remission has not been achieved.[3] Studies have shown that more than 60% of CD patients have small-bowel lesions,[2] and approximately 30% of patients have isolated SB involvement.[18] SBCE is extensively utilized in clinical practice to assess mucosal healing in confirmed CD patients during follow-up. In our analysis, we found that 66% pediatric CD patients had significant SB inflammation on SBCE despite endoscopic remission on ileocolonoscopy. Additionally, most of them had clinically inactive disease with wPCDAI $< 12.5$. Thus, SBCE examination is critical in achieving the therapeutic goal of treat to target regimens.

FC and CRP are the 2 most widely used biomarkers in IBD.[3] Compared with FC, serum CRP has higher specificity but low sensitivity.[19,20] In the present study, we also found FC to have significantly higher diagnostic accuracy for detecting SB
inflammation on SBCE compared to either CRP or ESR. The AUC of FC for presence of significant inflammatory activity in the SB was 0.691, which is similar to the results of previous studies,[21] or even higher than reported in other studies.[8,22,23] We studied the diagnostic accuracy of different cutoff values of FC in predicting SBCE findings and found the optimal cutoff value to be 242 μg/g, which is higher than reported by previous studies.[22,24] Our cutoff value is similar with that in the post hoc analysis of effect of tight control management on CD, which demonstrated that achieving FC < 250 μg/g was strongly associated with mucosal healing as defined by a CD Endoscopic Index of Severity < 4 and no deep ulcers.[24] A meta-analysis of 14 studies found that the sensitivity of FC with cutoff values of 50, 100, and 200 μg/g was 83%, 73%, and 50%, respectively, while the specificity was 50%, 73% and 88%, respectively. The meta-analysis recommended the FC cutoff of 100 μg/g to be used for screening SB CD; however, the studies included in this meta-analysis had patients with suspected CD and those being reevaluated for CD which can affect the cutoff value. A recent report on magnetic resonance imaging enterography-based follow-up of pediatric patients with CD reported a FC cutoff value of < 300 μg/g to identify children with mucosal healing (assessed by endoscopy).[27] The European Society for Pediatric Gastroenterology and Nutrition Gastroenterology Committee has suggested that endoscopic evaluation should be considered in pediatric IBD patients in clinical remission with a FC > 300 μg/g as this cut off level accurately predicts mucosal inflammation.[28]

Several studies have shown that FC level correlates with significant SB inflammation, and the correlation coefficient varies from 0.232 to 0.663.[6,8,22,30] Additionally, a number of studies have found no correlation between FC level and LS.[10,11] In our study, we found that there was no correlation between FC and LS, but it was weak (r = 0.30; P < .05), a finding that is similar to that reported by previous studies.[22,23]

There are very few studies on the role of FC in predicting moderate–severe inflammation on SBCE. A study by Kopylov et al had found that FC can be used as a predictor of significant SB inflammation (define significant inflammation as LS ≥ 790) with the AUC of 0.63.[21] The current study also had similar findings, and the cutoff value associated with the optimal combination of sensitivity and specificity in Kopylov et al was 275 μg/g, compared to 670 μg/g in our study.

There are a number of limitations in the current study, including its retrospective nature and small sample size; however, in this study, the stool collection for FC testing was carried out within 1 week before SBCE in order to avoid appearance of a long interval between FC level and SBCE. In addition, capsule readers were blinded to the FC results at the time of SBCE reporting.

In conclusion, measurement of FC is significant for predicting inflammatory activity in the SB and selecting eligible pediatric patients with known CD for SBCE.

Acknowledgments

The authors would like to thank Yi Zhang (Department of Clinical Epidemiology, Children’s Hospital of Fudan University, Shanghai, China) for his assistance with the statistical analysis.

Author contributions

Data curation: Shengnan Wang, Shijian Miao, Jie Wu, Xiaoxia Qiu, Yuhuan Wang.
Formal analysis: Shengnan Wang, Shijian Miao.
Methodology: Xiaoxia Qiu, Yuhuan Wang.
Software: Shengnan Wang.
Writing – original draft: Shengnan Wang.
Writing – review & editing: Shengnan Wang, Yuhuan Wang.

References

[1] Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–605.
[2] Voderholzer WA, Beinhoelzl J, Rogalla P, et al. Small bowel involvement in Crohn’s disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. Gut. 2005;54:369–73.
[3] Turner D, Ricciuto A, Lewis A, et al. STRIDE-I: an update on the selecting therapeutic targets in inflammatory Bowel Disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570–83.
[4] Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7–27.
[5] Friedlander JA, Liu Q, Tse B, et al. NASPGHAN capsule endoscopy clinical report. J Pediatr Gastroenterol. 2017;64:485–94.
[6] Iwamoto F, Matsuoka K, Motobayashi M, et al. Prediction of disease activity of Crohn’s disease through fecal calprotectin evaluated by balloon-assisted endoscopy. J Gastroenterol Hepatol. 2018;33:1984–9.
[7] Basso D, Zambon CF, Plebani M. Inflammatory bowel diseases: from pathogenesis to laboratory testing. Clin Chem Lab Med. 2014;52:471–81.
[8] Monteiro S, Barbosa M, Curdia GT, et al. Fecal Calprotectin as a selection tool for small bowel capsule endoscopy in suspected Crohn’s Disease. Inflamm Bowel Dis. 2018;24:2033–8.
[9] Vernia F, Di Ruscio M, Stefanelli G, et al. Is fecal calprotectin an accurate marker in the management of Crohn’s disease? J Gastroenterol Hepatol. 2020;35:390–400.
[10] Lowenberg M, Vermeire S, Mostafavi N, et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn’s Disease. Gastroenterology. 2019;157:997–1006.e6.
[11] Fireman Z, Mahajna E, Broide E, et al. Diagnosing small bowel Crohn’s disease with wireless capsule endoscopy. Gut. 2003;52:390–2.
[12] Grabnek IM, Defranschis R, Seidman E, et al. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther. 2008;27:146–54.
[13] Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1982;17:549–54.
[14] Turner D, Griffiths AM, Walters TD, et al. Mathematical weighting of the pediatric Crohn’s disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis. 2012;18:55–62.
[15] Available at: http://www.statsstutor.ac.uk/resources/uploaded/spearman.pdf.
[16] Jung ES, Lee SP, Kae SH, Kim JH, Kim HS, Jang HJ. Diagnostic accuracy of fecal calprotectin for the detection of Small Bowel Crohn’s Disease through capsule endoscopy: an updated meta-analysis and systematic review. Gut Liver. 2021;15:732–41.
[17] Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory Bowel Diseases. Gastroenterology. 2017;152:351–361.e5.
[18] Coene J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–94.
[19] Sands BE. Biomarkers of inflammation in inflammatory Bowel Disease. Gastroenterology. 2015;149:1275–1285.e2.
[20] Nakarai A, Kato J, Hiraoka S, et al. Slight increases in the disease activity index and platelet count imply the presence of active intestinal lesions in C-reactive protein-negative Crohn’s disease patients. Intern Med. 2014;53:1905–11.
[21] Kopylov U, Nemeth A, Koulouzidou Z, et al. Small bowel capsule endoscopy in the management of established Crohn’s disease: clinical impact, safety, and correlation with inflammatory biomarkers. Inflamm Bowel Dis. 2015;21:93–100.
[22] Bar-Gil SA, Koslowwsky B, Livovsky DM, et al. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel

---

**Table 4**

| Cutoff values | Sn | Sp | PPV | NPV |
|---------------|----|----|-----|-----|
| FC ≥ 280 μg/g | 92 | 49 | 30  | 97  |
| FC ≥ 670 μg/g | 69 | 67 | 33  | 90  |
| FC ≥ 1018 μg/g | 62 | 76 | 38  | 89  |

FC = fecal calprotectin, LS = Lewis score, NPV = negative predictive value, PPV = positive predictive value, Sn = sensitivity, Sp = specificity.
Crohn’s disease in patients undergoing capsule endoscopy. Scand J Gastroenterol. 2017;52:328–33.

[23] Aggarwal V, Day AS, Connor S, et al. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn’s disease to assess remission and predict relapse. Gastrointest Endosc. 2017;86:1070–8.

[24] Koulaouzidis A, Douglas S, Rogers MA, et al. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Scand J Gastroenterol. 2011;46:561–6.

[25] Jensen MD, Kjeldsen J, Nathans T. Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon. Scand J Gastroenterol. 2011;46:694–700.

[26] Reinisch W, Panaccione R, Bossuyt P, et al. Association of biomarker cutoffs and endoscopic outcomes in Crohn’s disease: a post hoc analysis from the CALM study. Inflamm Bowel Dis. 2020;26:1562–71.

[27] Weinstein-Nakar I, Focht G, Church P, et al. Associations among mucosal and transmural healing and fecal level of calprotectin in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2018;16:1089–1097.e4.

[28] Konincx CR, Donat E, Benninga MA, et al. The use of fecal calprotectin testing in paediatric disorders: a position paper of the European society for paediatric gastroenterology and nutrition gastroenterology committee. J Pediatr Gastroenterol Nutr. 2021;72:617–40.

[29] Koulaouzidis A, Sipponen T, Nemeth A, et al. Association between fecal calprotectin levels and small-bowel inflammation score in capsule endoscopy: a multicenter retrospective study. Dig Dis Sci. 2016;61:2033–40.

[30] Kawashima K, Ishihara S, Yuki T, et al. Fecal Calprotectin more accurately predicts endoscopic remission of Crohn’s disease than serological biomarkers evaluated using balloon-assisted enteroscopy. Inflamm Bowel Dis. 2017;23:2027–34.

[31] Olsen PA, Fossmark R, Qvigstad G. Fecal calprotectin in patients with suspected small bowel disease—a selection tool for small bowel capsule endoscopy? Scand J Gastroenterol. 2015;50:272–7.

[32] Sipponen T, Haapamaki J, Savilahti E, et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn’s disease detected by wireless capsule endoscopy. Scand J Gastroenterol. 2012;47:778–84.

[33] Kopylov U, Yablecovitch D, Lahat A, et al. Detection of Small Bowel mucosal healing and deep remission in patients with known small bowel crohn’s disease using biomarkers, capsule endoscopy, and imaging. Am J Gastroenterol. 2015;110:1316–23.